Company

Insilico Medicine

英矽智能

Insilico Medicine (英矽智能, 03696.HK) is a generative-AI-driven, clinical-stage biotech founded in 2014 by Alex Zhavoronkov, who serves as founder, CEO and chief business officer, with Feng Ren as co-CEO and chief scientific officer . Its model rests on the Pharma.AI platform, through which it has built a pipeline of over 30 programs across oncology, immunology, fibrosis and metabolism, while extending the platform into adjacent fields like advanced materials and agriculture . Its best-known asset is Rentosertib (ISM001-055), described as the world's first drug with both an AI-identified target and an AI-designed molecule, whose inhaled formulation received IND approval from China's CDE . On the business side, 13 of the world's top 20 pharma companies by revenue have signed software platform collaborations with it, and licensing deals on three pipelines with Exelixis, Menarini and others carry potential revenue of USD 2 billion . Insilico listed on HKEX on December 30, 2025 at HK$24.05 per share — the largest biotech IPO on the Hong Kong market that year — and opened at HK$35.00, a market cap of roughly HK$19.51 billion; Qiming Venture Partners, which led its Series B in 2019, held about 7% pre-IPO .

AI-generated — may contain errors, please verify.

Insilico MedicineCompany
英矽智能
渲染中…
Mentioned in 220 articles

Coverage